Protein Biomarkers for the Early Detection of Breast Cancer

Advances in breast cancer control will be greatly aided by early detection so as to diagnose and treat breast cancer in its preinvasive state prior to metastasis. For breast cancer, the second leading cause of cancer-related death among women in the United States, early detection does allow for increased treatment options, including surgical resection, with a corresponding better patient response. Unfortunately, however, many patients' tumors are diagnosed following metastasis, thus making it more difficult to successfully treat the malignancy. There are, at present, no existing validated plasma/serum biomarkers for breast cancer. Only a few biomarkers (such as HER-2/neu, estrogen receptor, and progesterone receptor) have utility for diagnosis and prognosis. Thus, there is a great need for new biomarkers for breast cancer. This paper will focus on the identification of new serum protein biomarkers with utility for the early detection of breast cancer.

[1]  J. Dennis,et al.  Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. , 1991, Cancer research.

[2]  C. Bertozzi,et al.  Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.

[3]  L. Perey,et al.  Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. , 1992, Cancer research.

[4]  Kelly K. Hunt,et al.  Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry , 2004, Breast Cancer Research and Treatment.

[5]  Lawrence B. Marks,et al.  The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™ , 2007 .

[6]  R. Salmon,et al.  Circulating antibodies against c‐MYC oncogene product in sera of colorectal cancer patients , 1990, International journal of cancer.

[7]  Cecelia E Schmalbach,et al.  Molecular profiling of the immune response in colon cancer using protein microarrays: Occurrence of autoantibodies to ubiquitin C‐terminal hydrolase L3 , 2003, Proteomics.

[8]  D. Hayes,et al.  Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. , 1989, Cancer communications.

[9]  D. Herceg,et al.  Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients , 2010, Medical oncology.

[10]  L. Liotta,et al.  Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer , 2002, Disease markers.

[11]  Daniel Pinkel,et al.  Genomic microarrays in human genetic disease and cancer. , 2003, Human molecular genetics.

[12]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Rouanet,et al.  Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women , 2009, Clinical Cancer Research.

[14]  Pauline M Rudd,et al.  Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. , 2003, Glycobiology.

[15]  D. Hayes,et al.  Clinical and Molecular Investigations of the DF3 Breast Cancer-Associated Antigen , 1989 .

[16]  S. Hirohashi,et al.  Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c‐erbB‐2 expression patterns in both the non‐invasive and invasive portions , 1998, Pathology international.

[17]  S M Hanash,et al.  Protein based microarrays: A tool for probing the proteome of cancer cells and tissues , 2001, Proteomics.

[18]  Mark Sutton-Smith,et al.  Characterization of the Oligosaccharides Associated with the Human Ovarian Tumor Marker CA125* , 2003, Journal of Biological Chemistry.

[19]  A. Kobata,et al.  Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours , 2005, Immunology and cell biology.

[20]  Bhupinder Bhullar,et al.  Self-Assembling Protein Microarrays , 2004, Science.

[21]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[22]  A. Paccagnella,et al.  Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. , 2002, European journal of cancer.

[23]  D. Lieberman.  How to screen for colon cancer. , 1998, Annual review of medicine.

[24]  Marie-Christine W. Gast,et al.  Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. , 2009, Oncology reports.

[25]  D. Albertson,et al.  Chromosome aberrations in solid tumors , 2003, Nature Genetics.

[26]  S. Lakhani,et al.  Molecular evolution of breast cancer , 2005, The Journal of pathology.

[27]  E. Diamandis,et al.  p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. , 2000, Clinical biochemistry.

[28]  Erik J. Erlandson,et al.  Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity , 2003, Proteomics.

[29]  P. Robbins,et al.  Glycotyping of prostate specific antigen. , 2000, Glycobiology.

[30]  I. Fentiman,et al.  Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. , 1998, European Journal of Cancer.

[31]  Joe W. Gray,et al.  Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Orntoft,et al.  Clinical aspects of altered glycosylation of glycoproteins in cancer , 1999, Electrophoresis.

[33]  Sunil R Lakhani,et al.  The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. , 2005, Pathology, research and practice.

[34]  P. V. van Diest,et al.  Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Goodarzi,et al.  Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[36]  Philippe Froguel,et al.  Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. , 2003, Human molecular genetics.

[37]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[38]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma , 2001, Cancer.

[39]  E. Kumpulainen,et al.  Serum Tumor Marker CA 15.3 and Stage are the Two Most Powerful Predictors of Survival in Primary Breast Cancer , 2002, Breast Cancer Research and Treatment.

[40]  A. Reiner,et al.  Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients , 2005, Journal of Cancer Research and Clinical Oncology.

[41]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[42]  Marcus Schmidt,et al.  Surface-enhanced Laser Desorption/Ionisation Time-of-flight Mass Spectrometry to Detect Breast Cancer Markers in Tears and Serum. , 2009, Cancer genomics & proteomics.

[43]  M. Ward,et al.  Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer , 2006, Journal of cellular biochemistry.

[44]  R. Molina,et al.  Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value , 2010, Tumor Biology.

[45]  M. Untch,et al.  Serum CEA and CA 15-3 as prognostic factors in primary breast cancer , 2002, British Journal of Cancer.

[46]  E. Wilkinson,et al.  Molecular and Morphologic Distinctions between Infiltrating Ductal and Lobular Carcinoma of the Breast , 2007, The breast journal.

[47]  W. Catalona,et al.  Management of cancer of the prostate. , 1994, The New England journal of medicine.

[48]  P. V. van Diest,et al.  Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution , 2001, The Journal of pathology.

[49]  D. Latchman,et al.  Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients , 1995, The Lancet.

[50]  Shu Zheng,et al.  Detection and identification of potential biomarkers of breast cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[51]  R. Dwek,et al.  Glycosylation and the immune system. , 2001, Science.

[52]  Jan F. Silverman,et al.  Molecular Evolutionary Patterns in Breast Cancer , 2003, Advances in anatomic pathology.

[53]  Marie-Christine W. Gast,et al.  Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. , 2009, The International journal of biological markers.

[54]  Joshua Labaer,et al.  Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. , 2011, Journal of proteome research.

[55]  R. Molina,et al.  Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. , 2003, Anticancer research.

[56]  M. Duffy,et al.  CA 15-3 and Related Mucins as Circulating Markers in Breast Cancer , 1999, Annals of clinical biochemistry.

[57]  Baruch S Blumberg,et al.  Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Yehia Mechref,et al.  Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. , 2008, Clinical chemistry.

[59]  S M Hanash,et al.  An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[61]  J. Taylor‐Papadimitriou,et al.  O-Linked Glycosylation in the Mammary Gland: Changes that Occur During Malignancy , 2001, Journal of Mammary Gland Biology and Neoplasia.

[62]  J. Dennis,et al.  Oncodevelopmental Expression of —GlcNAcβ1–6Manα1-6Manβ1— Branched Asparagine-linked Oligosaccharides in Murine Tissues and Human Breast Carcinomas , 1989 .

[63]  P. Rouanet,et al.  Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. , 2008, Journal of proteome research.

[64]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  S. Meijer,et al.  Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. , 1996, European journal of cancer.

[66]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[67]  Laurence Lodé,et al.  Surface‐enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node‐negative breast cancer tumors , 2006, Proteomics.

[68]  C G Chute,et al.  Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. , 1995, JAMA.

[69]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[70]  M. Gnant,et al.  p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. , 1997, European journal of cancer.

[71]  S. Ménard,et al.  Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.

[72]  E. Lynge.  Screening for cancer of the cervix uteri , 2005, World Journal of Surgery.

[73]  D. Germano,et al.  Lapatinib in breast cancer. , 2007, Annals of Oncology.

[74]  P. Speckman,et al.  Proteomic analysis of nipple aspirate fluid using SELDI‐TOF‐MS , 2005, International journal of cancer.

[75]  A. Andicoechea,et al.  Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. , 2006, Anticancer research.

[76]  D. Chan,et al.  Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid , 2005, Clinical Cancer Research.

[77]  Pauline M Rudd,et al.  A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. , 2008, Glycobiology.

[78]  M. Leal,et al.  Hepatitis E virus and HIV infection in homosexual men , 1995, The Lancet.

[79]  Yee Chan-Li,et al.  A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient , 2010, Breast Cancer Research and Treatment.

[80]  J. Eyfjörd,et al.  p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.

[81]  O. John Semmes,et al.  SELDI-TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast Cancers , 2004, Disease markers.

[82]  J. Minna,et al.  Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.

[83]  J. Biggart,et al.  c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. , 1992, Journal of clinical pathology.

[84]  Invasive Lobular Carcinoma , 2019, Breast Diseases.

[85]  S. Gendler,et al.  Structure and function of the cell surface (tethered) mucins. , 2008, Annual review of physiology.

[86]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[87]  H. Zentgraf,et al.  Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study , 1999, British Journal of Cancer.

[88]  Yao-Tseng Chen,et al.  Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. , 1998, Cancer research.

[89]  Denis Evoy,et al.  CA 15-3: uses and limitation as a biomarker for breast cancer. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[90]  David E. Misek,et al.  Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  Yanhui Hu,et al.  Next generation high density self assembling functional protein arrays , 2008, Nature Methods.

[92]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[93]  D. Grobbee,et al.  Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study , 2009, BMC Medical Genomics.

[94]  David E. Misek,et al.  Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. , 2004, Journal of proteome research.

[95]  Sylvain Julien,et al.  Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis , 2011, Breast Cancer Research.

[96]  J. A. Ferguson.  Early detection of unsuspected colon cancers in asymptomatic people , 1993, Diseases of the colon and rectum.

[97]  Yehia Mechref,et al.  Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. , 2010, Analytical chemistry.

[98]  Jame Abraham,et al.  Lapatinib in the treatment of breast cancer , 2007, Expert review of anticancer therapy.

[99]  W. Caspary,et al.  p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. , 1996, Pancreas.

[100]  L. Perey,et al.  Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. , 1992, Cancer research.

[101]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[102]  T. Pawlik,et al.  Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein , 2006, BMC Cancer.

[103]  R. Gelber,et al.  Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  D. Horsfall,et al.  Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.

[105]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[106]  Roland Eils,et al.  High-Resolution Genomic Profiling Reveals Association of Chromosomal Aberrations on 1q and 16p with Histologic and Genetic Subgroups of Invasive Breast Cancer , 2006, Clinical Cancer Research.

[107]  J. Taylor‐Papadimitriou,et al.  The ST6GalNAc-I Sialyltransferase Localizes throughout the Golgi and Is Responsible for the Synthesis of the Tumor-associated Sialyl-Tn O-Glycan in Human Breast Cancer* , 2006, Journal of Biological Chemistry.

[108]  B De La Lande,et al.  Prognostic value of CA 15.3 kinetics for metastatic breast cancer. , 2002, The International journal of biological markers.

[109]  D. Shen,et al.  Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. , 2007, International journal of oncology.

[110]  K. Aoki,et al.  Targeted glycoproteomic identification of biomarkers for human breast carcinoma. , 2008, Journal of proteome research.

[111]  Emanuel F. Petricoin,et al.  Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer , 2007, Annals of Surgical Oncology.

[112]  G. Serio,et al.  p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. , 1992, American journal of clinical pathology.

[113]  C. Isacke,et al.  A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. , 2007, European journal of cancer.

[114]  I. Ellis,et al.  p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.